Dilantin and Omnicef drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Dilantin (phenytoin sodium) and Omnicef (cefdinir). Common drug interactions include depression among females and convulsion among males.

The phase IV clinical study analyzes what interactions people have when they take Dilantin and Omnicef. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Dilantin?

Dilantin has active ingredients of phenytoin sodium. It is often used in epilepsy. eHealthMe is studying from 20,858 Dilantin users. Check the latest studies of Dilantin.

What is Omnicef?

Omnicef has active ingredients of cefdinir. It is often used in sinusitis. eHealthMe is studying from 2,774 Omnicef users. Check the latest studies of Omnicef.



On Jul, 04, 2026

14 people who take Dilantin and Omnicef together, and have interactions are studied.

Dilantin and Omnicef drug interactions.

What are the common drug interactions of Dilantin and Omnicef, by gender? *:

female:

  1. Depression
  2. Drug abuse
  3. Drug abuser
  4. Drug hypersensitivity
  5. Drug screen positive
  6. Dry mouth
  7. Epistaxis (bleed from the nose)
  8. Fall
  9. Flatulence (flatus expelled through the anus)
  10. Gastritis (inflammation of stomach)

male:

  1. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
  2. Nausea (feeling of having an urge to vomit)
  3. Renal failure chronic (long lasting kidney dysfunction)
  4. Weight decreased
  5. Anaemia (lack of blood)
  6. Anaemia of chronic disease
  7. Bronchitis chronic (inflammation of the mucous membrane in the bronchial tubes- chronic)
  8. Hypertensive heart disease
  9. Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
  10. Lobar pneumonia (a form of pneumonia that affects a large and continuous area of the lobe of a lung)

What are the common drug interactions of Dilantin and Omnicef, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
  2. Drug toxicity
  3. Gait disturbance
  4. Joint stiffness
  5. Prostatitis (inflammation of the prostate gland)
  6. Therapeutic response decreased (less preventive response)

20-29:

n/a

30-39:

  1. Drug abuse
  2. Drug abuser
  3. Drug screen positive
  4. Fall
  5. Flatulence (flatus expelled through the anus)
  6. Gastritis (inflammation of stomach)
  7. Gastroenteritis (inflammation of stomach and intestine)
  8. Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
  9. Grand mal convulsion (a type of generalized seizure that affects the entire brain)
  10. Haematemesis (vomiting of blood)

40-49:

  1. Back pain
  2. Intracranial venous sinus thrombosis (presence of thrombosis (a blood clot) in the dural venous sinuses, which drain blood from the brain)
  3. Tachycardia (a heart rate that exceeds the range of 100 beats/min)

50-59:

  1. Acute respiratory failure
  2. Oedema peripheral (superficial swelling)
  3. Pneumonia streptococcal (pneumonia, caused by streptococcus pneumoniae)
  4. Renal failure chronic (long lasting kidney dysfunction)
  5. Weight decreased
  6. Anaemia (lack of blood)
  7. Anaemia of chronic disease
  8. Blood pressure increased
  9. Bronchitis chronic (inflammation of the mucous membrane in the bronchial tubes- chronic)
  10. Diabetic retinopathy (damage to the retina caused by complications of diabetes)

60+:

  1. Drug hypersensitivity

What are the existing conditions these people have? *

  1. Pain: 3 people, 21.43%
  2. Glioblastoma (most common and most aggressive malignant primary brain tumour in humans): 3 people, 21.43%
  3. Sleep Disorder: 2 people, 14.29%
  4. Depression: 2 people, 14.29%
  5. Renal Cell Carcinoma Stage Iv (stage iv renal cell cancer have cancer that has spread to other organs, such as the lungs, liver, bones, or brain, and may have spread to lymph nodes): 1 person, 7.14%
  6. Reduction Of Increased Intracranial Pressure (reducing intracranial pressure): 1 person, 7.14%
  7. Menopausal Symptoms: 1 person, 7.14%
  8. Gastrointestinal Disorder (functional problems of gastrointestinal tract): 1 person, 7.14%
  9. Csf Volume Increased: 1 person, 7.14%
  10. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Dilantin and Omnicef?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Dilantin and Omnicef:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Dilantin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Omnicef:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Dilantin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Omnicef and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on phenytoin sodium and cefdinir (the active ingredients of Dilantin and Omnicef, respectively), and Dilantin and Omnicef (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: